Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients

American Surgeon

Volumn 79, Issue 7, 2013, Pages 716-722

  Burnett, Nicolas P ^a   Dunki Jacobs, Erik M ^a   Callender, Glenda G ^a   Anderson, Ryan J ^a   Scoggins, Charles R ^a   Mcmasters, Kelly M ^a   Martin, Robert C G ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BARCELONA CLINIC LIVER CANCER STAGING; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GROUPS BY AGE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; SEX RATIO;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879683450     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Martin RC II, Loehle J, Scoggins CR, McMasters KM. Kentucky hepatoma: epidemiologic variant or same problem in a different region? Arch Surg 2007;142:431-6; discussion 436-7.
2. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010;42:341-7.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(suppl 1):S35-50. (Pubitemid 39423368)
4. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2011;7:463-75.
5. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(suppl 4):5-13.
6. Wei S, Hao X, Zhan D, et al. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci 2011;31:637-41.
7. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723-31.
8. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(suppl 1):8-17. (Pubitemid 34702014)
9. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
10. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211, v.
11. Schiffman SC, Woodall CE, Kooby DA, et al. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carcinoma: a multicenter analysis. J Surg Oncol 2010;101:105-10.
12. Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7.
13. Botha JF, Langnas AN. Liver transplantation for hepatocellular carcinoma: an update. J Natl Compr Canc Netw 2006;4:762-7. (Pubitemid 44412393)
14. Mergental H, Adam R, Ericzon BG, et al. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 2012;18:297-305.
15. Worns MA, Bosslet T, Victor A, et al. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012;47:718-28.
16. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-54. (Pubitemid 40781067)
17. Schacherer D, Schoelmerich J, Zuber-Jerger I. [The diagnostic approach to hepatocellular carcinoma] [in German]. Z Gastroenterol 2007;45:1067-74.
18. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007;11:1-206.
19. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:133-41. (Pubitemid 29287619)
20. Muscari F, Guinard JP, Kamar N, et al. Impact of preoperative alpha-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg 2012;25:1824-31.
21. Gomez-Rodriguez R, Romero-Gutierrez M, Artaza-Varasa T, et al. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 2012;104:298-304.
22. Wang Y, Chen Y, Ge N, et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol 2012;25:3540-6.
23. Giannini EG, Marenco S, Borgonovo G, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012;26:1371-9.